Common oncology diseases and potential research directions

（1）Early detection, diagnosis, prognosis evaluation, and prediction of treatment response in malignant tumors.

（2）Development of novel molecular classification systems to guide precision oncology.

（3）Mechanistic studies on tumor progression and therapeutic resistance, including identification of actionable targets.

（1）Non-Invasive Lung Cancer Diagnosis Based on Salivary Metabolomics
Adv. Sci. 2025, 2416719 (IF = 14.3)

Research Objective:
Utilizing HuiJian’s proprietary metabolomics MS LOC platform integrated with AI algorithms, this study aimed to identify salivary metabolic biomarkers and develop a screening model for lung cancer.

Study Cohort:
A cross-sectional study including 1,043 participants: 429 healthy volunteers, 280 patients with benign pulmonary diseases, and 334 lung cancer patients.

Key Findings:
1. Salivary metabolic biomarkers identified through the integrated platform revealed lung cancer–associated metabolic disturbances in saliva.
2. The AI-driven screening model demonstrated superior performance compared to conventional clinical tumor markers, highlighting its strong potential for fully non-invasive lung cancer detection.

（2）Lipid Metabolism-Based Subtyping of Triple-Negative Breast Cancer and Identification of Therapeutic Targets
Cell Metab. 2021, 33(1), 51–64 (IF = 29.0)

Research Objective:
To develop a novel molecular subtyping system for triple-negative breast cancer (TNBC) based on tissue-specific metabolic profiles, and to explore corresponding precision treatment strategies.

Study Cohort:
Cohort 1 (Subtype Discovery): Tumor tissues from 360 TNBC patients and matched adjacent normal tissues from 88 cases.
Cohort 2 (Subtype Validation): Tumor tissues from an independent cohort of 72 TNBC patients.

Key Findings:
1. A novel molecular subtyping system for TNBC was established based on lipid metabolic features, with each subtype exhibiting distinct clinical characteristics (including prognosis) and metabolic signatures.
2. Subtype II, associated with the poorest prognosis, showed increased sensitivity to glycolysis inhibitors. Combining glycolysis inhibition with immunotherapy significantly enhanced treatment efficacy for this subtype.

（3）Mechanistic Study of Metastasis in Acute Myeloid Leukemia (AML)
Acta Pharm Sin B. 2024, 14(10), 4461–4477 (IF = 14.9)

Research Objective:
To uncover the mechanisms driving metastasis in acute myeloid leukemia (AML) and explore potential therapeutic strategies.

Study Cohort:
Sample Set 1: Liver metastases, normal liver tissues, and serum samples from AML mouse models.
Sample Set 2: Bone marrow mononuclear cells from six newly diagnosed AML patients and ten control subjects.

Key Findings:
1. Integrated multi-omics analysis revealed significant disruptions in multiple metabolic pathways—including arginine and proline metabolism—in liver metastases of AML.
2. Creatine was found to promote AML cell proliferation both in vitro and in vivo. Conversely, inhibition of the creatine transporter Slc6a8 using Ompenaclid effectively suppressed AML progression and liver metastasis.
3. Creatine and Slc6a8 exert pro-tumor effects by enhancing oxidative phosphorylation and glycolysis in AML cells.